Abstract
A 29-year-old male patient with a history of neurofibromatosis type II and bilateral vestibular schwannomas was referred for evaluation of new-onset proteinuria. The patient’s schwannomas were inoperable, and he was treated with bevacizumab 10mg/kg intravenously every 3 weeks. After 18 months of therapy, serial imaging showed stabilization of the schwannoma size and sequential monitoring of urine analyses showed new-onset proteinuria without changes in kidney function. Bevacizumab was discontinued and he was referred for nephrology evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
